Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Secchiero

Showing results (31-40 of 212) with videos related to

Pageof 22
Sort By:
Frontiers in Medicine|August 1, 2022
Therapeutic potential of the MDM2 inhibitor Nutlin-3 in counteracting SARS-CoV-2 infection of the eye through p53 activationGiorgio Zauli, Sara AlHilali, Samar Al-Swailem, et al.
International Journal of Molecular Sciences|March 11, 2023
Lipids at the Nexus between Cerebrovascular Disease and Vascular Dementia: The Impact of HDL-Cholesterol and CeramidesDomenico Sergi, Enrico Zauli, Veronica Tisato, et al.
Atherosclerosis|March 18, 2010
Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarctionPaola Secchiero, Arianna Gonelli, Federica Corallini, et al.
Blood|June 24, 2004
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSFGiorgio Zauli, Erika Rimondi, Vanessa Nicolin, et al.
The International Journal of Biochemistry & Cell Biology|October 1, 2016
Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activityRebecca Voltan, Paola Secchiero, Fabio Casciano, et al.
Journal of Experimental Pharmacology|September 10, 2025
Targeting Intestinal Permeability for Graft-versus-Host Disease Treatment: A Therapeutic Perspective with DefibrotideErika Rimondi, Elisabetta Melloni, Paola Secchiero, et al.
Investigational New Drugs|January 4, 2011
TRAIL shows potential cardioprotective activityBarbara Toffoli, Stella Bernardi, Riccardo Candido, et al.
Acta Diabetologica|April 26, 2013
The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40Paola Secchiero, Barbara Toffoli, Elisabetta Melloni, et al.
Clinics (Sao Paulo, Brazil)|January 30, 2014
Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cellsVeronica Tisato, Alessia Norcio, Claudio Celeghini, et al.
Expert Opinion on Drug Delivery|August 21, 2015
Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug deliveryStefania Biffi, Rebecca Voltan, Enrico Rampazzo, et al.
Pageof 22

Showing results (31-40 of 212) with videos related to

Sort By:
Pageof 22
Frontiers in Medicine|August 1, 2022
Therapeutic potential of the MDM2 inhibitor Nutlin-3 in counteracting SARS-CoV-2 infection of the eye through p53 activationGiorgio Zauli, Sara AlHilali, Samar Al-Swailem, et al.
International Journal of Molecular Sciences|March 11, 2023
Lipids at the Nexus between Cerebrovascular Disease and Vascular Dementia: The Impact of HDL-Cholesterol and CeramidesDomenico Sergi, Enrico Zauli, Veronica Tisato, et al.
Atherosclerosis|March 18, 2010
Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarctionPaola Secchiero, Arianna Gonelli, Federica Corallini, et al.
Blood|June 24, 2004
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSFGiorgio Zauli, Erika Rimondi, Vanessa Nicolin, et al.
The International Journal of Biochemistry & Cell Biology|October 1, 2016
Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activityRebecca Voltan, Paola Secchiero, Fabio Casciano, et al.
Journal of Experimental Pharmacology|September 10, 2025
Targeting Intestinal Permeability for Graft-versus-Host Disease Treatment: A Therapeutic Perspective with DefibrotideErika Rimondi, Elisabetta Melloni, Paola Secchiero, et al.
Investigational New Drugs|January 4, 2011
TRAIL shows potential cardioprotective activityBarbara Toffoli, Stella Bernardi, Riccardo Candido, et al.
Acta Diabetologica|April 26, 2013
The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40Paola Secchiero, Barbara Toffoli, Elisabetta Melloni, et al.
Clinics (Sao Paulo, Brazil)|January 30, 2014
Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cellsVeronica Tisato, Alessia Norcio, Claudio Celeghini, et al.
Expert Opinion on Drug Delivery|August 21, 2015
Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug deliveryStefania Biffi, Rebecca Voltan, Enrico Rampazzo, et al.
Pageof 22